Literature DB >> 2945510

PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

A B Young, J B Penney, S Starosta-Rubinstein, D S Markel, S Berent, B Giordani, R Ehrenkaufer, D Jewett, R Hichwa.   

Abstract

Fifteen drug-free patients with early to midstage Huntington's disease were evaluated with quantitative neurological examinations, scales for functional capacity, computed tomographic (CT) scans, and positron emission tomographic (PET) scans of 18F-2-fluoro-2-deoxyglucose (18F-FDG) uptake. All patients had abnormal indices of caudate metabolism on PET scanning, whereas in patients with early disease indices of putamen metabolism and CT measures of caudate atrophy were normal. Indices of caudate metabolism correlated highly with the patients' overall functional capacity (r = 0.906; p less than 0.001) and bradykinesia/rigidity (r = -0.692; p less than 0.01). Indices of putamen metabolism correlated highly with motor functions: chorea (r = -0.841; p less than 0.01), oculomotor abnormalities (r = -0.849; p less than 0.01), and fine motor coordination (r = -0.866; p less than 0.01). Indices of thalamic metabolism correlated positively with dystonia (r = 0.559; p less than 0.05). The data suggest that PET scanning with 18F-FDG is a sensitive measure of brain dysfunction in Huntington's disease and that basal ganglia metabolism is highly correlated with the overall functional capacity of individual patients and with the degree of their motor abnormalities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945510     DOI: 10.1002/ana.410200305

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

1.  Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Authors:  A S Harris; E M Denovan-Wright; L C Hamilton; H A Robertson
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

Review 2.  PET and movement disorders.

Authors:  D J Brooks; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Neural bases of dysphoria in early Huntington's disease.

Authors:  Sergio Paradiso; Beth M Turner; Jane S Paulsen; Ricardo Jorge; Laura L Boles Ponto; Robert G Robinson
Journal:  Psychiatry Res       Date:  2008-01-15       Impact factor: 3.222

Review 4.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

Review 5.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 6.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.

Authors:  H D Rosas; A S Feigin; Steven M Hersch
Journal:  NeuroRx       Date:  2004-04

Review 7.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

9.  Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.

Authors:  Juan Carlos Molano-Eslava; Angela Iragorri-Cucalón; Gonzalo Ucrós-Rodríguez; Carolina Bonilla-Jácome; Santiago Tovar-Perdomo; David V Herin; Luis Orozco-Cabal
Journal:  Rev Colomb Psiquiatr       Date:  2008-10-01

Review 10.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.